Questions and answers on bovine spongiform encephalopathies (BSE) and vaccines - Scientific guideline
Table of contents
This is an update of the information in the public statement on the evaluation of bovine spongiform encephalopathies (BSE) - risk via the use of materials of bovine origin in or during the manufacture of vaccines and the questions and answers on bovine spongiform encephalopathies (BSE) and vaccines.
Keywords: BSE safety, TSE, vaccines, vaccine manufacture, bovine materials, CJD, prions, gelatin, bovine serum, milk derivatives, polysorbate, tallow
-
List item
Questions and answers on bovine spongiform encephalopathies (BSE) and vaccines - Revision 1 (PDF/134.3 KB)
Adopted
First published: 08/11/2018
EMA/CHMP/BWP/192228/2017 -
List item
Overview of comments received on ‘Questions and Answers on bovine spongiform encephalopathies (BSE) and vaccines’ (EMA/CHMP/BWP/192228/2017) - Revision 1 (PDF/119.23 KB)
Adopted
First published: 08/11/2018
EMA/CHMP/BWP/637549/2018 -
List item
Draft questions and answers on bovine spongiform encephalopathies (BSE) and vaccines - Revision 1 (PDF/149.07 KB)
Draft: consultation closed
First published: 01/02/2018
Last updated: 01/02/2018
Consultation dates: 01/02/2018 to 31/07/2018
EMA/CHMP/BWP/192228/2017 -
List item
Questions and answers on bovine spongiform encephalopathies (BSE) and vaccines - First version (PDF/59.49 KB)
Adopted
First published: 24/04/2001
Last updated: 24/04/2001
Legal effective date: 23/04/2001
EMEA/CPMP/BWP/819/01 -
List item
Public statement on the evaluation of bovine spongiform encephalopathies (BSE) - risk via the use of materials of bovine origin in or during the manufacture of vaccines (PDF/21.44 KB)
Adopted
First published: 28/02/2001
Last updated: 28/02/2001
Legal effective date: 28/02/2001
EMEA/CPMP/BWP/476/01